Clinical Trial Update: Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats [Phase 2]

View source ↗

Summary

Open-label Phase 2 trial assessing efficacy and safety of olaparib in patients with BRCA1/BRCA2 mutations across ovarian, breast, prostate, and pancreatic cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Prostate Cancer

Drugs mentioned

• Lynparza (olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Ovarian, Breast | Phase 2 | Status: COMPLETED | Results posted: 2015-05-22